+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hypoparathyroidism - Market Insight, Epidemiology and Market Forecast - 2046

  • ID: 5357288
  • Report
  • July 2021
  • Region: Global
  • 135 pages
  • DelveInsight

FEATURED COMPANIES

  • Ascendis Pharma
  • EnteraBio
  • Shire (Takeda)
This ‘Hypoparathyroidism -Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Hypoparathyroidism market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Hypoparathyroidism market size from 2018 to 2030. The Report also covers current Hypoparathyroidism treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030

Hypoparathyroidism Disease Understanding and Treatment Algorithm

Hypoparathyroidism (hypoPTH) is a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone or lacks biological activity. The parathyroid glands are part of the endocrine system - the network of glands that secrete hormones into the bloodstream, where they travel to various body areas. These hormones regulate the chemical processes (metabolism) that influence various organs and activities within the body. Hormones are involved in numerous vital processes, including regulating heart rate, body temperature, blood pressure, cell differentiation and growth, and modulation of several metabolic processes. Parathyroid hormone (along with vitamin D and the hormone calcitonin, which is produced by the thyroid gland) plays a role in regulating the levels of calcium and phosphorus in the blood and in determining bone growth and bone cell activity. Due to a deficiency of the parathyroid hormone, individuals may exhibit abnormally low levels of calcium in the blood (hypocalcemia) and high levels of phosphorus (hyperphosphatemia).

Hypoparathyroidism Diagnosis

A diagnosis of hypoPTH is made based upon the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized tests. Blood tests can reveal abnormal levels of calcium, phosphorus, magnesium, creatinine, and intact parathyroid hormone. Urine tests can reveal if the body is excreting too much calcium.

In addition, the Food and Drug Administration (FDA) has approved the use of the synthetic parathyroid hormone teriparatide as a diagnostic agent to distinguish hypoPTH from pseudohypoparathyroidism.

Additional tests may be performed to detect complications that may be associated with hypoPTH. For example, an electrocardiogram, a test that records the heart's electrical activity, can reveal arrhythmias that are sometimes associated with low calcium levels and hypoPTH. An ophthalmologic exam should also be done to check for cataracts.

Hypoparathyroidism Treatment

Unlike most other hormonal deficits, hypoPTH is not treated with replacing the missing hormone, parathyroid hormone (PTH).

Currently, the standard treatment consists of activated vitamin D (calcitriol) and calcium supplements. Some people may also need magnesium supplementation. Conventional therapy requires many pills taken throughout the day.

Diet recommendations usually include eating foods high in calcium, such as dairy products, breakfast cereals, fortified orange juice, and green, leafy vegetables, or avoiding foods high in phosphorus, such as meat, poultry, fish, nuts, whole grains, and beans. Conventional therapy with vitamin D and calcium may lead to a buildup of calcium in the kidneys. This buildup may lead to problems, including kidney stones and deposits of calcium, reduced kidney function, tissue damage, or even kidney failure. In January 2015, the US Food and Drug Administration approved PTH 1-84 for adult hypoPTH patients who do not respond well to standard treatment as an add-on to that treatment

Hypoparathyroidism Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Hypoparathyroidism, Diagnosed Prevalent Cases of Hypoparathyroidism, Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism, Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism, Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism, and Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Key Findings
  • The total prevalent population of hypoparathyroidism in the 7MM ranges from 262,542 in 2020 growing at a CAGR of 1.22% during the study period [2018-2030].
  • Among the European five countries, Germany had the highest prevalent population of hypoparathyroidism with 28,604 cases, followed by UK and France in 2020. On the other hand, Spain had the lowest prevalent population.
  • Japan had 33,276 prevalent cases of hypoparathyroidism in 2020.
  • As per the analysis, a higher percentage of prevalence was observed for females, in comparison to males, in all the 7MM countries.
  • According to the analysis, it has been observed that hypoparathyroidism prevalence varied across the 7MM countries, based on the age-specific prevalence of the disease. For instance, the highest proportion was observed in the 65+ Years age group in the US, while in the EU-5 countries, people aged 55-64 Years accounted for the maximum patient pool.
  • Among the major types of hypoparathyroidism, i.e., Chronic and transient hypoparathyroidism, the former one accounts for a higher number of prevalent cases of hypoparathyroidism.
Hypoparathyroidism Epidemiology

The epidemiology segment also provides the Hypoparathyroidism epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hypoparathyroidism Drug Chapters

Hypoparathyroidism Marketed Drugs

Natpara (parathyroid hormone/rhPTH [1-84]): Shire (Takeda)

Natpara (parathyroid hormone) for injection is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. The drug is a bioengineered replica of the human parathyroid hormone. It was approved in the US, and EU in 2015, and 2017, respectively. But in September 2019, the company recalled the drug from the US market.

Hypoparathyroidism Emerging Drugs

TransCon PTH: Ascendis Pharma

TransCon PTH is an investigational prodrug of parathyroid hormone (PTH) and is under development as a once-daily hormone replacement therapy. It is designed to restore physiologic levels of PTH for 24 h each day. The company believes that this therapy can address both the short-term symptoms and long-term complications of hypoparathyroidism (HP).

The company's goal is to provide a PTH replacement therapy that normalizes serum and urinary calcium, as well as serum phosphate levels, and improves the quality of life. In September 2020, the company submitted an amendment to IND to initiate PaTHway, a global Phase III clinical trial evaluating the safety, tolerability, and efficacy of the therapy in adults with HP following discussions with FDA and European regulatory authorities. In addition, the company is planning to conduct a Phase III study in Japan designed to evaluate the safety, tolerability, and efficacy of the therapy

EB612: EnteraBio

EB612, an oral human parathyroid hormone (1-34) (PTH), the parathyroid glands are part of the endocrine system, a network of glands that secrete hormones into the bloodstream, which then travel to various areas of the body. PTH (along with vitamin D and the hormone calcitonin, which the thyroid gland produces) plays a role in regulating the levels of calcium and phosphorus in the blood. Due to a deficiency of PTH, individuals may exhibit abnormally low levels of calcium in the blood (hypocalcemia) and high levels of phosphorus (hyperphosphatemia). The common practice in treating these patients is with calcium and Vitamin D supplements at high doses in addition to other various drugs to treat the symptoms

Hypoparathyroidism Market Outlook

Hypoparathyroidism is a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone or the parathyroid hormone produced lacks biological activity. The parathyroid glands are part of the endocrine system, the network of glands that secrete hormones into the bloodstream, where they travel to various areas of the body. The severity of the condition can range from mild symptoms such as a tingling or numbness in the fingers, toes, or around the lips (paresthesias) to severe muscle cramps and muscle spasms.

The treatment of hypoparathyroidism is directed toward the specific symptoms that are apparent in each individual and the lab tests. Treatment is aimed at raising calcium levels high enough to provide symptom relief without causing abnormally high levels of calcium in the blood (hypercalcemia) or the urine (hypercalciuria). The specific therapies used may vary depending upon the disease severity, the specific symptoms present, an individual's age and overall health, personal preference, and additional factors.

Oral calcium supplements can increase calcium levels in the blood. However, at high doses, calcium supplements can cause gastrointestinal side effects, such as constipation, in some people. There are several different types of calcium supplements available. Some brands may work better for certain people. High doses of vitamin D, generally in the form of calcitriol, can help the body absorb calcium and eliminate phosphorus. Another form of vitamin D that may be used is ergocalciferol or cholecalciferol. Outside the US, doctors use alpha calcidol. Ergocalciferol and cholecalciferol have a longer duration of action than calcitriol or alpha calcidol because the former two forms of vitamin D are stored in the body for long times.

If the magnesium level is low and the patient experiences symptoms of hypoparathyroidism, the doctor may recommend taking a magnesium supplement. If the calcium levels remain low even with treatment, thiazide diuretics can help decrease the amount of calcium lost through the urine. However, some people with hypoparathyroidism, including people who inherited the condition, should not take thiazide diuretics.

Some individuals, especially those with severe symptoms due to low blood calcium levels, may require immediate relief through intravenous calcium therapy, even if their calcium levels are only mildly reduced. Intravenous therapy means that a substance (e.g., calcium) is delivered into the bloodstream through an injection or infusion directly into a vein.

Furthermore, some may be encouraged to make dietary changes to help treat their condition. Affected individuals may be encouraged to eat foods high in calcium, such as dairy products, breakfast cereals, and fortified orange juice, and green, leafy vegetables.

Key Findings
  • The market size of hypoparathyroidism in the 7MM was anticipated to be USD 247 million in 2020, at a CAGR of 17.70% for the study period (2018-2030).
  • The current therapeutic landscape of hypoparathyroidism in the 7MM is driven by several approved therapy, including those with off-labeled products.
  • Natpara (parathyroid hormone/rhPTH [1-84]) is the only approved drug for the treatment of hypoparathyroidism, which is approved in the US as well as in Europe.
  • Of all the therapies, in the 7MM the majority of the market share is accommodated by TransCon PTH, which is expected to generate a market size of USD 1,615 million, in 2030.
Ascendis Pharma's TransCon PTH, a long-acting version of PTH, showed strong data in a Phase II trial. It eliminated the need for a standard of care - defined as active vitamin D and ≤600 mg/day of calcium supplements - in around 91% of subjects and maintained calcium in the normal range. TransCon platform could prove to be a major value driver for the hypoparathyroidism market, making TransCon PTH a competitor of Natpara. Apart from TransCon PTH, EB612 has also continued to make good progress for hypoparathyroidism. It has been observed that oral PTH is effectively delivered into the bloodstream and activates PTH-dependent biological pathways inadequately activated in patients with hypoparathyroidism. As per the analysis, TransCon PTH was found to be the most promising upcoming drug, followed by EB612 (PTH 1-34) and Encaleret. The analysis is based on different parameters such as efficacy, safety, ROA, and various other factors, further explained in detail in the attribute analysis.

The United States Market Outlook

This section provides the total Hypoparathyroidism market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total Hypoparathyroidism market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Hypoparathyroidism market size and market size by therapies in Japan are provided.

Hypoparathyroidism Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Hypoparathyroidism market or expected to get launched in the market during the study period 2018-2030. The analysis covers the Hypoparathyroidism market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hypoparathyroidism Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapies.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Hypoparathyroidism emerging therapies.

Reimbursement Scenario in Hypoparathyroidism

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, the publisher considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

The publisher performs competitive and market Intelligence analysis of the Hypoparathyroidism market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Hypoparathyroidism, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Hypoparathyroidism epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hypoparathyroidism is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Hypoparathyroidism market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Hypoparathyroidism market.
Report Highlights
  • The robust pipeline with novel MOA and oral ROA, increasing prevalence, effectiveness of drugs as both mono and combination therapy will positively drive the Hypoparathyroidism market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hypoparathyroidism R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Hypoparathyroidism. The launch of emerging therapies will significantly impact the Hypoparathyroidism market.
  • The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Hypoparathyroidism Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Hypoparathyroidism Pipeline Analysis
  • Hypoparathyroidism Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Hypoparathyroidism Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
- Hypoparathyroidism Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Hypoparathyroidism Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis
Key Questions Answered

Market Insights:
  • What was the Hypoparathyroidism market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Hypoparathyroidism total market size as well as market size by therapies across the 7MM during the forecast period (2021-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Hypoparathyroidism market size during the forecast period (2021-2030)?
  • At what CAGR, the Hypoparathyroidism market is expected to grow at the 7MM level during the forecast period (2021-2030)?
  • What would be the Hypoparathyroidism market outlook across the 7MM during the forecast period (2021-2030)?
  • What would be the Hypoparathyroidism market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risk, burdens, and unmet needs of Hypoparathyroidism?
  • What is the historical Hypoparathyroidism patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Hypoparathyroidism at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hypoparathyroidism?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Hypoparathyroidism during the forecast period (2021-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Hypoparathyroidism along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Hypoparathyroidism in the US and Europe?
  • What are the Hypoparathyroidism marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Hypoparathyroidism?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Hypoparathyroidism?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypoparathyroidism therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hypoparathyroidism and their status?
  • What are the key designations that have been granted for the emerging therapies for Hypoparathyroidism?
  • What are the 7MM historical and forecasted market of Hypoparathyroidism?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving Hypoparathyroidism.
  • To understand the future market competition in the Hypoparathyroidism market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Hypoparathyroidism in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Hypoparathyroidism market.
  • To understand the future market competition in the Hypoparathyroidism market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Ascendis Pharma
  • EnteraBio
  • Shire (Takeda)
1 Key Insights

2 Report Introduction

3 Hypoparathyroidism Market Overview at a Glance
3.1 Market Share by Therapies (%) Distribution of Hypoparathyroidism in 2018
3.2 Market Share by Therapies (%) Distribution of Hypoparathyroidism in 2030

4 Executive Summary of Hypoparathyroidism

5 Key Events

6 Disease Background and Overview
6.1 Introduction
6.2 Causes of Hypoparathyroidism
6.3 Symptoms of Hypoparathyroidism
6.4 Mechanisms/pathophysiology Hypoparathyroidism
6.5 Diagnosis of Hypoparathyroidism
6.5.1 Guidelines for diagnosis and evaluation
6.5.2 European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults

7 Treatment
7.1 Management of Hypoparathyroidism: Summary Statement and Guidelines
7.2 European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism (HypoPT) in adults
7.3 The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism
7.4 Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus

8 Epidemiology and Patient Population
8.1 Key Findings
8.2 Epidemiology Methodology
8.3 Total Prevalent Cases of Hypoparathyroidism in the 7MM
8.4 Total Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM
8.5 Epidemiology of Hypoparathyroidism
8.6 The United States
8.6.1 Prevalent Cases of Hypoparathyroidism in the United States
8.6.2 Diagnosed Prevalent Cases of Hypoparathyroidism in the United States
8.6.3 Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States
8.6.4 Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States
8.6.5 Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States
8.6.6 Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States
8.7 EU5
8.7.1 Prevalent Cases of Hypoparathyroidism in EU5
8.7.2 Diagnosed Prevalent Cases of Hypoparathyroidism in EU5
8.7.3 Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5
8.7.4 Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5
8.7.5 Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5
8.7.6 Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5
8.8 Japan
8.8.1 Prevalent Cases of Hypoparathyroidism in Japan
8.8.2 Diagnosed Prevalent Cases of Hypoparathyroidism in Japan
8.8.3 Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan
8.8.4 Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan
8.8.5 Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan
8.8.6 Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan

9 Organizations contributing towards Hypoparathyroidism

10 Patient Journey

11 Marketed Drugs
11.1 Natpara (parathyroid hormone/rhPTH[1-84]): Shire (Takeda)
11.1.1 Product Description
11.1.2 Regulatory Milestones
11.1.3 Clinical Development
11.1.4 Clinical Trials Information
11.1.5 Safety and Efficacy
11.1.6 Product Profile

12 Emerging Therapies
12.1 Key Cross
12.2 TransCon PTH: Ascendis Pharma
12.2.1 Drug Description
12.2.2 Other Developmental Activities
12.2.3 Clinical Development
12.2.4 Clinical Trials Information
12.2.5 Safety and Efficacy
12.2.6 Product Profile
12.3 EB612: EnteraBio
12.3.1 Drug Description
12.3.2 Other Developmental Activities
12.3.3 Clinical Development
12.3.4 Clinical Trials Information
12.3.5 Safety and Efficacy
12.3.6 Product Profile
12.4 Encaleret (BBP-305/CLTX-305): Bridgebio/Calcilytix Therapeutics
12.4.1 Drug Description
12.4.2 Other Developmental Activities
12.4.3 Clinical Development
12.4.4 Clinical Trials Information
12.4.5 Safety and Efficacy
12.4.6 Product Profile

13 Potential of Current Therapies and Emerging Therapies

14 Hypoparathyroidism: Seven Major Market Analysis
14.1 Key Findings
14.2 Market Methodology
14.3 Market Size of Hypoparathyroidism in the 7MM in USD Million (2018-2030)
14.4 Market Size of Hypoparathyroidism by Therapies in the 7MM
14.5 Market Outlook
14.6 Attribute Analysis
14.7 Key Market Forecast Assumptions
14.8 United States Market Size
14.8.1 Total Market Size of Hypoparathyroidism in the United States
14.8.2 Market Size of Hypoparathyroidism by Therapies in the United States
14.9 EU-5 Market Size
14.9.1 Total Market size of Hypoparathyroidism in Europe
14.9.2 Market Size of Hypoparathyroidism by Therapies in Europe
14.1 Japan
14.10.1 Total Market size of Hypoparathyroidism in Japan
14.10.2 Market Size of Hypoparathyroidism by Therapies in Japan

15 KOL Views

16 Market Drivers

17 Market Barriers

18 SWOT Analysis

19 Unmet Needs

20 Reimbursement and Market Access

21 Appendix
21.1 Bibliography
21.2 Report Methodology

22 Publisher Capabilities

23 Disclaimer

24 About the Publisher

List of Tables
Table 1: Summary of Hypoparathyroidism Market, and Epidemiology (2018-2030)
Table 2: Key Events
Table 3: Acute and chronic manifestations of hypocalcemia and hypoparathyroidism
Table 4: Total Prevalent Cases of Hypoparathyroidism in the 7MM, in Thousand (2018-2030)
Table 5: Total Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM, in Thousand (2018-2030)
Table 6: Total Prevalent Cases of Hypoparathyroidism in the United States, in Thousand (2018-2030)
Table 7: Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in Thousand (2018-2030)
Table 8: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the US, in Thousand (2018-2030)
Table 9: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in Thousand (2018-2030)
Table 10: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in Thousand (2018-2030)
Table 11: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in Thousand (2018-2030)
Table 12: Total Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Table 13: Total Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Table 14: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Table 15: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Table 16: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Table 17: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Table 18: Total Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Table 19: Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Table 20: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Table 21: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Table 22: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Table 23: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Table 24: Organizations contributing toward Hypoparathyroidism
Table 25: Natpara/rhPTH(1-84), Clinical Trial Description, 2021
Table 26: Comparison of emerging drugs under development
Table 27: TransCon PTH, Clinical Trial Description, 2021
Table 28: EB612, Clinical Trial Description, 2021
Table 29: Encaleret, Clinical Trial Description, 2021
Table 30: Market Size of Hypoparathyroidism in the 7MM in USD Million (2018-2030)
Table 31: Market Size of Hypoparathyroidism by therapies in the 7MM, in USD Million (2018-2030)
Table 32: Key Market Forecast Assumptions for Natpara
Table 33: Key Market Forecast Assumptions for TransCon PTH
Table 34: Key Market Forecast Assumptions for EB612
Table 35: Key Market Forecast Assumptions for Encaleret (BBP-305/CLTX-305)
Table 36: US Market Size of Hypoparathyroidism in USD Million (2018-2030)
Table 37: Market Size of Hypoparathyroidism by therapies in the US, in USD Million (2018-2030)
Table 38: EU5 Market Size of Hypoparathyroidism in USD Million (2018-2030)
Table 39: Market Size of Hypoparathyroidism by therapies in EU5, in USD Million (2018-2030)
Table 40: Japan Market Size of Hypoparathyroidism in USD Million (2018-2030)

List of Figures
Figure 1: Anatomy of Thyroid and parathyroid glands
Figure 2: Symptoms of Hypoparathyroidism
Figure 3: Total Prevalent Cases of Hypoparathyroidism in the 7MM, in Thousand (2018-2030)
Figure 4: Total Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM, in Thousand (2018-2030)
Figure 5: Total Prevalent Cases of Hypoparathyroidism in the United States, in Thousand (2018-2030)
Figure 6: Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in Thousand (2018-2030)
Figure 7: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the US, in Thousand (2018-2030)
Figure 8: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in Thousand (2018-2030)
Figure 9: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in Thousand (2018-2030)
Figure 10: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in Thousand (2018-2030)
Figure 11: Total Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Figure 12: Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Figure 13: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Figure 14: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Figure 15: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Figure 16: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in Thousand (2018-2030)
Figure 17: Total Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Figure 18: Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Figure 19: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Figure 20: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Figure 21: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Figure 22: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in Thousand (2018-2030)
Figure 23: Market Size of Hypoparathyroidism in the 7MM in USD Million (2018-2030)
Figure 24: Seven Major Market Size of Hypoparathyroidism by Therapies in the 7MM, in USD Million (2018-2030)
Figure 25: Market Size of Hypoparathyroidism in the US, USD Millions (2018-2030)
Figure 26: Market Size of Hypoparathyroidism by therapies in the United States, in USD Million (2018-2030)
Figure 27: Market Size of Hypoparathyroidism in EU5, USD Million (2018-2030)
Figure 28: EU5 Market Size of Hypoparathyroidism by Therapies in USD Million (2018-2030)
Figure 29: Market Size of Hypoparathyroidism in Japan, USD Million (2018-2030)
Figure 30: Japan Market Size of Hypoparathyroidism by Therapies in USD Million (2018-2030)
Figure 31: Market Drivers
Figure 32: Market Barriers
Figure 33: SWOT Analysis
Figure 34: Unmet Needs
Note: Product cover images may vary from those shown
  • Shire (Takeda)
  • Ascendis Pharma
  • EnteraBio
  • Bridgebio/Calcilytix Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll